Moderna Reports Promising Response Rates For Skin Cancer Combo Therapy In Resistant Patients

1. Moderna presents Phase 1/2 data for mRNA-4359 at a major oncology congress. 2. Combination therapy shows a 24% objective response rate in melanoma patients. 3. Higher response rate of 67% seen in PD-L1+ tumors among evaluated patients. 4. Ongoing studies of mRNA-4359 in melanoma and non-small cell lung cancer continue. 5. New COVID-19 vaccine formula shows a significant immune response increase.